ÂÜÀòÂÒÂ×

Conor O'Donovan has extensive experience in regulatory affairs within the pharmaceutical industry. Conor is currently serving as the Vice President of Regulatory Affairs at Gossamer Bio since 2020. Prior to this role, they worked as the Executive Director of Regulatory Affairs at Gossamer Bio from July 2020 to May 2023.

Before joining Gossamer Bio, Conor held the position of Senior Director of Regulatory Affairs and CMC Regulatory at Retrophin from September 2018 to June 2020. In this role, they were responsible for the development and execution of European regulatory strategy for clinical-phase products aimed at treating rare diseases. Conor also served as the Global CMC Regulatory lead for the development of small molecule drugs.

Conor's previous experience includes roles at Orexigen Therapeutics, where they worked as the Senior Director and Director of CMC Regulatory Affairs from January 2017 to August 2018. Conor also worked at IQVIA as a Global Regulatory Affairs Manager from July 2015 to December 2016.

Earlier in their career, Conor served in various roles at the Health Products Regulatory Authority (HPRA) from August 2005 to July 2015. These roles included Senior Pharmaceutical Assessor, Executive Pharmaceutical Assessor, and Pharmaceutical Assessor. Conor was involved in reviewing marketing authorizations, providing scientific advice, and reviewing clinical trial applications. Conor also had recruitment, mentoring, and line management responsibilities within the assessment team.

Conor's career in the pharmaceutical industry began in 2002, where they worked as a Pharmacist and Pharmacy Manager at Community Clinical Pharmacy until July 2005.

Conor O'Donovan first pursued their education from 1997 to 2001 at Trinity College Dublin, where they obtained a Bachelor of Science in Pharmacy. After a gap of several years, they returned to academia and attended University College Dublin from 2007 to 2009, where they completed a Diploma in business studies. In 2014, Conor enrolled in the Institute of Technology, Sligo, and successfully completed a Master of Science in Biopharmaceutical Science in 2017.